Regenxbio (RGNX) Reports Q2 EPS of $0.30; Announces Positive Interim Update from RGX-314 Phase I Clinical Trial for Wet AMD

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/1/2026

1. INTC
2. AMZN
3. RDDT
4. PINS
5. COIN
6. FSLR
7. SYK
8. MA
9. FND
10. DASH

Go back to Regenxbio (RGNX) Reports Q2 EPS of $0.30; Announces Positive Interim Update from RGX-314 Phase I Clinical Trial for Wet AMD

REGENXBIO Reports Second Quarter 2018 Financial and Operating Results and Interim Data from Ongoing Clinical Trials for Wet Age-Related Macular Degeneration and Homozygous Familial Hypercholesterolemi

August 8, 2018 7:30 AM EDT

ROCKVILLE, Md., Aug. 8, 2018 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced financial results for the quarter ended June 30, 2018 and recent operational highlights, including updates to interim data from its ongoing clinical trials.

"We are very encouraged by the positive interim data for RGX-314 and the potential of NAV gene therapy as a one-time treatment for wet AMD, particularly as this is a non-rare patient population with a... More